Literature DB >> 21799009

Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Henrik Gårdsvoll1, Benedikte Jacobsen, Mette C Kriegbaum, Niels Behrendt, Lars Engelholm, Søren Østergaard, Michael Ploug.   

Abstract

The urokinase-type plasminogen activator receptor (uPAR) is a glycolipid-anchored membrane protein with an established role in focalizing uPA-mediated plasminogen activation on cell surfaces. Distinct from this function, uPAR also modulates cell adhesion and migration on vitronectin-rich matrices. Although uPA and vitronectin engage structurally distinct binding sites on uPAR, they nonetheless cooperate functionally, as uPA binding potentiates uPAR-dependent induction of lamellipodia on vitronectin matrices. We now present data advancing the possibility that it is the burial of the β-hairpin in uPA per se into the hydrophobic ligand binding cavity of uPAR that modulates the function of this receptor. Based on these data, we now propose a model in which the inherent interdomain mobility in uPAR plays a major role in modulating its function. Particularly one uPAR conformation, which is stabilized by engagement of the β-hairpin in uPA, favors the proper assembly of an active, compact receptor structure that stimulates lamellipodia induction on vitronectin. This molecular model has wide implications for drug development targeting uPAR function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21799009      PMCID: PMC3190949          DOI: 10.1074/jbc.M111.220087

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris.

Authors:  Magnus Kjaergaard; Henrik Gårdsvoll; Daniel Hirschberg; Steen Nielbo; Anand Mayasundari; Cynthia B Peterson; Anna Jansson; Thomas J D Jørgensen; Flemming M Poulsen; Michael Ploug
Journal:  Protein Sci       Date:  2007-09       Impact factor: 6.725

Review 2.  Proteolytic interstitial cell migration: a five-step process.

Authors:  Peter Friedl; Katarina Wolf
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

3.  Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.

Authors:  Qing Huai; Aiwu Zhou; Lin Lin; Andrew P Mazar; Graham C Parry; Jennifer Callahan; David E Shaw; Bruce Furie; Barbara C Furie; Mingdong Huang
Journal:  Nat Struct Mol Biol       Date:  2008-03-23       Impact factor: 15.369

4.  Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.

Authors:  Henrik Gårdsvoll; Michael Ploug
Journal:  J Biol Chem       Date:  2007-03-13       Impact factor: 5.157

Review 5.  The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.

Authors:  B Jacobsen; M Ploug
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  The three-fingered protein domain of the human genome.

Authors:  A Galat
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

7.  A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Authors:  Thore Hillig; Lars H Engelholm; Signe Ingvarsen; Daniel H Madsen; Henrik Gårdsvoll; Jørgen K Larsen; Michael Ploug; Keld Danø; Lars Kjøller; Niels Behrendt
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

8.  Structure and ligand interactions of the urokinase receptor (uPAR).

Authors:  Magnus Kjaergaard; Line V Hansen; Benedikte Jacobsen; Henrik Gardsvoll; Michael Ploug
Journal:  Front Biosci       Date:  2008-05-01

9.  Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.

Authors:  Jesper Pass; Annika Jögi; Ida K Lund; Birgitte Rønø; Morten G Rasch; Henrik Gårdsvoll; Leif R Lund; Michael Ploug; John Rømer; Keld Danø; Gunilla Høyer-Hansen
Journal:  Thromb Haemost       Date:  2007-06       Impact factor: 5.249

10.  The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.

Authors:  Roman M Salasznyk; Maria Zappala; Mingzhe Zheng; Lin Yu; Cynthia Wilkins-Port; Paula J McKeown-Longo
Journal:  Matrix Biol       Date:  2007-02-06       Impact factor: 11.583

View more
  34 in total

1.  The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Authors:  Henrik Gårdsvoll; Mette C Kriegbaum; Emil P Hertz; Warner Alpízar-Alpízar; Michael Ploug
Journal:  J Histochem Cytochem       Date:  2013-07-29       Impact factor: 2.479

2.  Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Authors:  Julie M Leth; Haydyn D T Mertens; Katrine Zinck Leth-Espensen; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2019-03-20       Impact factor: 5.157

3.  GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Authors:  Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

4.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

5.  Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Authors:  Timmy Mani; Degang Liu; Donghui Zhou; Liwei Li; William Eric Knabe; Fang Wang; Kyungsoo Oh; Samy O Meroueh
Journal:  ChemMedChem       Date:  2013-10-02       Impact factor: 3.466

6.  Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain.

Authors:  Wanee Plengpanich; Stephen G Young; Weerapan Khovidhunkit; André Bensadoun; Hirankorn Karnman; Michael Ploug; Henrik Gårdsvoll; Calvin S Leung; Oludotun Adeyo; Mikael Larsson; Suwanna Muanpetch; Supannika Charoen; Loren G Fong; Sathit Niramitmahapanya; Anne P Beigneux
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

7.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

8.  A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Haydyn D T Mertens; Magnus Kjaergaard; Simon Mysling; Henrik Gårdsvoll; Thomas J D Jørgensen; Dmitri I Svergun; Michael Ploug
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

9.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

10.  Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling.

Authors:  Nicoleta L Popa; Jon E Wergedal; K-H William Lau; Subburaman Mohan; Charles H Rundle
Journal:  J Bone Miner Metab       Date:  2013-05-23       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.